TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

Soleno Therapeutics, Inc. has secured a loan and security agreement with Oxford Finance LLC for up to $200 million, aiming to enhance its financial standing for the anticipated commercial launch ...

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright raised their price target on the stock from $70.00 to $100.00.

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing ...

Soleno Therapeutics (NASDAQ:SLNO – Free Report) had its price target hoisted by Stifel Nicolaus from $74.00 to $108.00 in a research note issued to investors on Friday,Benzinga reports.

Soleno Therapeutics CFO sells over $399k in company stock Open in App ...